U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859268) titled 'A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals with Obesity' on Feb. 28.
Brief Summary: This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Study Start Date: April, 2025
Study Ty...